The aims of the HASD Neuropathology Core D and Brain Tissue Bank are: 1. To make neuropathologic diagnoses on all new brain accessions from HASD research subjects using standard diagnostic criteria where possible. Alzheimer's disease lesion severity will be quantified using the staging scheme of Braak and Braak (1991 and 2006). The neuropathologic diagnosis of Alzheimer's disease (AD) is based on NIA-Reagan Institute (1997), the Consortium to Establish a Registry for Alzheimer's Disease (CERAD;1997), and Khachaturian (1985) criteria. The severity of Lewy body pathology will be assessed using the criteria of Braak et a/. (2003) and the diagnosis of dementia with Lewy bodies will be determined using the criteria of McKeith et a/. (2005). Neuropathologic diagnostic criteria for frontotemporal lobar degeneration will be determined using the consensus criteria of Cairns et a/. (2007). Other criteria will be applied where appropriate. 2. To perform brain autopsies and to collect, store at -80?C, and distribute frozen and formalin fixed, paraffin wax-embedded tissues to support HASD projects and investigators and outside collaborations that complement in-house research. 3. To maintain a neuropathology computerized database in concert with the Biostatistics and Clinical Cores and the Washington University Neuroscience Blueprint Interdisciplinary Center Core (P30-NS057105). Information stored will include macroscopic images of fresh and fixed brain, demographic data, diagnoses, semi-quantitative morphometric data, neuropathology reports (in collaboration with Dr Schmidt, Chair, Division of Neuropathology), bibliographic information, and data relevant to Core tissue banking activities. In addition, neuropathology data will be transferred, after Biostatistics Core quality control and validation, to the National Alzheimer Coordinating Center (NACC), Washington University, Seattle, WA (U01-AG016976). 4. To establish Consensus Criteria for the Neuropathologic Diagnosis of Early AD. A major achievement of this project will be the establishment of new pathological diagnostic criteria for the earliest brain changes of AD. Using immunohistochemical and stereological methods the early changes associated with disease will be quantified and consensus criteria developed. Together, this project and the supporting cores will define the earliest pathological and biochemical stages of AD in comparison with healthy brain aging. To accomplish these aims, Core D will work closely with other Cores, Core leaders and Project leaders. There is no budgetary or scientific overlap with the activities of the Neuropathology Core and Brain Tissue Bank of the Washington University Alzheimer's Disease Research Center (ADRC).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-30
Application #
8425012
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
30
Fiscal Year
2013
Total Cost
$204,056
Indirect Cost
$69,808
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Lucey, Brendan P; Mawuenyega, Kwasi G; Patterson, Bruce W et al. (2016) Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol :
Esparza, Thomas J; Wildburger, Norelle C; Jiang, Hao et al. (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Sci Rep 6:38187
McKee, Ann C; Cairns, Nigel J; Dickson, Dennis W et al. (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 131:75-86
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Jin, Sheng Chih; Benitez, Bruno A; Deming, Yuetiva et al. (2016) Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. Methods Mol Biol 1303:299-314
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Van Schependom, Jeroen; Jain, Saurabh; Cambron, Melissa et al. (2016) Reliability of measuring regional callosal atrophy in neurodegenerative diseases. Neuroimage Clin 12:825-831
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50
Su, Yi; Rubin, Brian B; McConathy, Jonathan et al. (2016) Impact of MR-Based Attenuation Correction on Neurologic PET Studies. J Nucl Med 57:913-7
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9

Showing the most recent 10 out of 756 publications